日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma.

RUNX2 抑制会破坏 PAX3::FOXO1-RUNX2 前馈环路,并瓦解融合阳性横纹肌肉瘤中的致癌基因程序

Mendes Elizabeth A, Munshi Aanandi, Singh Archana, Evans Maisie D, Chou Hsien-Chao, Kim Yong Yean, Song Young, Jo Ara, Lee Daniel, Ciampi Jaida, Chambers Audrey, Weitzel Samantha, Deel Michael, Bentley Rex C, Khan Javed, Green Darrell, Linardic Corinne M

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

横纹肌肉瘤患者新型药物优先排序:儿童肿瘤协作组(COG)横纹肌肉瘤新型药物工作组报告

Pacenta, Holly L; Allen-Rhoades, Wendy; Langenau, David; Houghton, Peter J; Keller, Charles; Heske, Christine M; Deel, Michael D; Linardic, Corinne M; Shern, Jack F; Stewart, Elizabeth; Turpin, Brian; Harrison, Douglas J; Khan, Javed; Mascarenhas, Leo; Skapek, Stephen X; Meyer, William H; Hawkins, Douglas S; Chen, Eleanor Y; Amatruda, James F; Hingorani, Pooja; Laetsch, Theodore W

Advances in the management of pediatric genitourinary rhabdomyosarcoma

儿童泌尿生殖系统横纹肌肉瘤治疗进展

Deel, Michael D